Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Asthma is a common chronic disease that affects over 300 million people worldwide. Between 5% and 10% of this population has severe asthma, which often remains uncontrolled despite maximal conventional treatment. Omalizumab is a recombinant humanised monoclonal antibody that binds circulating IgE antibody and decreases allergic, IgE-mediated airway inflammation.1 In the USA and many other countries, omalizumab is approved for the treatment of adults and adolescents aged 12 years and above with moderate-to-severe persistent allergic asthma, whose symptoms are poorly controlled with inhaled corticosteroids (ICS). European approval stipulates that patients should have a history of frequent, severe exacerbations despite receiving ICS in high doses combined with an inhaled long-acting β2 agonist bronchodilator (LABA). The European license also includes children aged …
Correction notice This article has been corrected since it was published Online First. The word ‘exacerbation’ has been corrected to ‘exacerbations’ in the article title.
Competing interests NCT has participated in advisory boards and/or received consultancy fees from Asmacure, Chiesi and Respivert. He has received lecture fees from Boston Scientific, Chiesi, GlaxoSmithKline and Novartis, and industry-sponsored grant funding to the University of Glasgow from AstraZeneca, Boston Scientific, Genentech, GlaxoSmithKline, Novartis, Pfizer and Synairgen for participating in clinical trials.